Session » (1272–1305) Pediatric Rheumatology – Clinical Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1287

A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1290

Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)

10:30AM-12:30PM: Abstract Number: 1274

Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation

10:30AM-12:30PM: Abstract Number: 1297

Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.

10:30AM-12:30PM: Abstract Number: 1292

Childhood-onset Behçet’s disease: HLA alleles role on diagnosis and treatment in a Latin American tertiary center

10:30AM-12:30PM: Abstract Number: 1284

Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1305

Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study

10:30AM-12:30PM: Abstract Number: 1277

Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease

10:30AM-12:30PM: Abstract Number: 1278

Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus

10:30AM-12:30PM: Abstract Number: 1302

Dose Adjustment was Necessary in Patients with Cryopyrin-Associated Periodic Syndrome Switching from Anakinra to Canakinumab

10:30AM-12:30PM: Abstract Number: 1273

Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1281

Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1275

Fostering connections in Pediatric Rheumatology: A Narrative medicine intervention

10:30AM-12:30PM: Abstract Number: 1291

Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures

10:30AM-12:30PM: Abstract Number: 1298

Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups

10:30AM-12:30PM: Abstract Number: 1303

Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study

10:30AM-12:30PM: Abstract Number: 1283

Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1294

Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous

10:30AM-12:30PM: Abstract Number: 1300

International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry

10:30AM-12:30PM: Abstract Number: 1280

Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis

10:30AM-12:30PM: Abstract Number: 1285

Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls

10:30AM-12:30PM: Abstract Number: 1288

Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?

10:30AM-12:30PM: Abstract Number: 1296

Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience

10:30AM-12:30PM: Abstract Number: 1289

Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus

10:30AM-12:30PM: Abstract Number: 1276

Mental Health Screening Implementation for Pediatric Rheumatology Patients at a Tertiary Academic Medical Center

10:30AM-12:30PM: Abstract Number: 1295

Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America

10:30AM-12:30PM: Abstract Number: 1299

Pediatric Antiphospholipid Syndrome in a Large Tertiary Center

10:30AM-12:30PM: Abstract Number: 1301

Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1282

Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)

10:30AM-12:30PM: Abstract Number: 1286

Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1293

Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study

10:30AM-12:30PM: Abstract Number: 1304

The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study

10:30AM-12:30PM: Abstract Number: 1279

Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].